通往有效和可获得的埃博拉病毒抗体疗法之路

IF 5.7 2区 医学 Q1 VIROLOGY Current opinion in virology Pub Date : 2022-06-01 DOI:10.1016/j.coviro.2022.101210
Hugues Fausther-Bovendo , Gary Kobinger
{"title":"通往有效和可获得的埃博拉病毒抗体疗法之路","authors":"Hugues Fausther-Bovendo ,&nbsp;Gary Kobinger","doi":"10.1016/j.coviro.2022.101210","DOIUrl":null,"url":null,"abstract":"<div><p>Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and local economies. Effective vaccines and treatments against EBOV are therefore needed to limit the impact of this deadly disease. In 2019, a hallmark clinical trial demonstrated the efficacy of monoclonal antibody (mAb) against EBOV. Despite, this recent success, survival of individuals with high viremia remains low. Effective immunotherapies against other Ebolavirus species are still under pre-clinical development. More importantly, the cost of immunotherapies is prohibitive to most individual and affected countries. Novel manufacturing and administration strategies of mAb protein or genetic information could substantially reduce the cost of immunotherapies; hence making them valuable tools against EBOV and other infectious agents.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625722000190/pdfft?md5=c0ae1bfacd20a3feddc57027002349ce&pid=1-s2.0-S1879625722000190-main.pdf","citationCount":"5","resultStr":"{\"title\":\"The road to effective and accessible antibody therapies against Ebola virus\",\"authors\":\"Hugues Fausther-Bovendo ,&nbsp;Gary Kobinger\",\"doi\":\"10.1016/j.coviro.2022.101210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and local economies. Effective vaccines and treatments against EBOV are therefore needed to limit the impact of this deadly disease. In 2019, a hallmark clinical trial demonstrated the efficacy of monoclonal antibody (mAb) against EBOV. Despite, this recent success, survival of individuals with high viremia remains low. Effective immunotherapies against other Ebolavirus species are still under pre-clinical development. More importantly, the cost of immunotherapies is prohibitive to most individual and affected countries. Novel manufacturing and administration strategies of mAb protein or genetic information could substantially reduce the cost of immunotherapies; hence making them valuable tools against EBOV and other infectious agents.</p></div>\",\"PeriodicalId\":11082,\"journal\":{\"name\":\"Current opinion in virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1879625722000190/pdfft?md5=c0ae1bfacd20a3feddc57027002349ce&pid=1-s2.0-S1879625722000190-main.pdf\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1879625722000190\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625722000190","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 5

摘要

埃博拉病毒(EBOV)爆发可夺去数千人的生命,使卫生保健系统和地方经济瘫痪。因此,需要针对EBOV的有效疫苗和治疗,以限制这一致命疾病的影响。2019年,一项标志性的临床试验证明了单克隆抗体(mAb)抗EBOV的有效性。尽管最近取得了成功,但高病毒血症患者的存活率仍然很低。针对其他埃博拉病毒种类的有效免疫疗法仍处于临床前开发阶段。更重要的是,免疫疗法的费用对大多数个人和受影响的国家来说是令人望而却步的。mAb蛋白或遗传信息的新制造和管理策略可以大大降低免疫治疗的成本;因此,它们成为对抗埃博拉病毒和其他感染病原体的宝贵工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The road to effective and accessible antibody therapies against Ebola virus

Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and local economies. Effective vaccines and treatments against EBOV are therefore needed to limit the impact of this deadly disease. In 2019, a hallmark clinical trial demonstrated the efficacy of monoclonal antibody (mAb) against EBOV. Despite, this recent success, survival of individuals with high viremia remains low. Effective immunotherapies against other Ebolavirus species are still under pre-clinical development. More importantly, the cost of immunotherapies is prohibitive to most individual and affected countries. Novel manufacturing and administration strategies of mAb protein or genetic information could substantially reduce the cost of immunotherapies; hence making them valuable tools against EBOV and other infectious agents.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.80
自引率
5.10%
发文量
76
审稿时长
83 days
期刊介绍: Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.
期刊最新文献
Advancing zoonotic respiratory virus research through the use of organoids. Editorial Board Koala retrovirus and neoplasia: correlation and underlying mechanisms Modeling zoonotic and vector-borne viruses Oncogenic Animal Herpesviruses
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1